News ESMO26: AZ's claudin ADC doubles survival in GI cancers AstraZeneca's CLARITY-Gastric01 trial of sone-ve in CLDN18.2-positive gastrointestinal cancers reveals a 53% reduction in the risk of death.
News UK biotech financing shoots up, setting up "a record year" UK biotech shrugged off a difficult economic environment with a 44% increase in venture capital investment in the third quarter to £270m, says BIA.
News ESMO26: Roche's KRAS drug tops approved drugs in NSCLC In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met high expectations, with a head-to-head win over Lumakras and Krazati.
News UK puts £100m into "world-first" AI biosecurity facility The UK government will unveil a big investment package in AI in the Budget this week, headlined by £100m in funding for an AI Biosecurity Lab.
News ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.
News ESMO26: Bayer's Nubeqa finds new prostate cancer role Bayer's prostate cancer drug Nubeqa has reduced the risk of the disease spreading or death by 58% in patients at high risk of disease recurrence.
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.